• +1-646-491-9876
    • +91-20-67278686

    Search

    NAD Dependent Protein Deacetylase Sirtuin 1-Pipeline Review H1 2017

    NAD Dependent Protein Deacetylase Sirtuin 1-Pipeline Review H1 2017

    • Report Code ID: RW0001834425
    • Category Pharmaceuticals
    • No. of Pages 46
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) - Pipeline Review, H1 2017

    Summary

    According to the recently published report 'NAD Dependent Protein Deacetylase Sirtuin 1 - Pipeline Review, H1 2017'; NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) pipeline Target constitutes close to 12 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes.

    NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) - NAD-dependent deacetylase sirtuin-1 is a protein encoded by the SIRT1 gene. It modulates chromatin function through deacetylation of histones and can promote alterations in the methylation of histones and DNA, leading to transcriptional repression. It is essential in skeletal muscle cell differentiation and in response to low nutrients mediates the inhibitory effect on skeletal myoblast differentiation which also involves 5'-AMP-activated protein kinase (AMPK) and nicotinamide phosphoribosyltransferase (NAMPT) .

    The report 'NAD Dependent Protein Deacetylase Sirtuin 1 - Pipeline Review, H1 2017' outlays comprehensive information on the NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

    It also reviewsalso reviews key players involved in NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Preclinical stages are 2, 1 and 5 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Gastrointestinal, Metabolic Disorders, Central Nervous System, Genetic Disorders, Infectious Disease and Respiratory which include indications Non Alcoholic Fatty Liver Disease (NAFLD) , Non-Alcoholic Steatohepatitis (NASH) , Type 2 Diabetes, Bacterial Pneumonia, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) , Chronic Obstructive Pulmonary Disease (COPD) , Emphysema, Ewing Sarcoma, Pancreatic Cancer, Parkinson's Disease, Peritonitis, Solid Tumor and Spinocerebellar Ataxia (SCA) .

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.)
    - The report reviews NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) targeted therapeutics and enlists all their major and minor projects
    - The report assesses NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) - Overview
    NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) - Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Products under Development by Universities/Institutes
    NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) - Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) - Companies Involved in Therapeutics Development
    Bial - Portela & Ca SA
    GlaxoSmithKline Plc
    Jyant Technologies Inc
    NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) - Drug Profiles
    (leucine + metformin hydrochloride + sildenafil citrate) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (leucine + metformin hydrochloride) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (leucine + PDE5 Inhibitor) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Drugs to Inhibit Sirtuin 1 for Ewing Sarcoma - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    JOT-104 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    JOT-105 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    resveratrol - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    resveratrol - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    resveratrol - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit SIRT1 for Chronic Myelogenous Leukemia - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SRT-3025 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    toxoflavin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) - Dormant Products
    NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) - Discontinued Products
    NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) - Product Development Milestones
    Featured News & Press Releases
    Jun 10, 2016: NuSirt Biopharma Presenting New Research at American Diabetes Association's 76th Annual Scientific Sessions
    Jun 10, 2016: NuSirt Biopharma Presents Data on NS-0200 at American Diabetes Association's 76th Annual Scientific Sessions
    May 18, 2016: NuSirt Biopharma to Present at American Diabetes Association's 76th Scientific Sessions
    Jan 26, 2016: Clinical Trial Results Show Synergy between NuSirt Technology and Metformin in Patients with Type 2 Diabetes
    Dec 10, 2015: NuSirt Biopharma Receives FDA Fast Track Designation for Non-Alcoholic Fatty Liver Disease Treatment
    Oct 08, 2015: NuSirt Biopharma Plans Clinical Trial in Non-Alcoholic Fatty Liver Disease
    Jun 25, 2015: New Study: NuSirt Technology Demonstrates Potential as New Type 2 Diabetes Therapy
    Jun 06, 2015: NuSirt Biopharma Presenting New Data On Leucine-Metformin Combination at American Diabetes Association 75th Scientific Sessions
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Indication, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products under Investigation by Universities/Institutes, H1 2017
    Products under Investigation by Universities/Institutes, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Pipeline by Bial - Portela & Ca SA, H1 2017
    Pipeline by GlaxoSmithKline Plc, H1 2017
    Pipeline by Jyant Technologies Inc, H1 2017
    Dormant Products, H1 2017
    Dormant Products, H1 2017 (Contd..1) , H1 2017
    Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Top 10 Indications, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Bial - Portela & Ca SA
    GlaxoSmithKline Plc
    Jyant Technologies Inc

    Request for Sample

    Report Url https://www.reportsweb.com//nad-dependent-protein-deacetylase-sirtuin-1-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//nad-dependent-protein-deacetylase-sirtuin-1-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//nad-dependent-protein-deacetylase-sirtuin-1-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments